阿片类使用障碍药物治疗获取中的种族不平等
该研究利用2016—2019年Medicare按服务收费受益人40%随机样本,纳入因残疾参保且发生OUD相关索引事件(急诊或住院非致死性过量、注射用药相关感染住院、住院或寄宿康复/脱毒)的黑人、西班牙裔和白人患者。共识别23,370名受益人的25,904次索引事件,其中黑人占15.2%、西班牙裔占8.1%、白人占76.7%。索引事件后180天内,黑人、西班牙裔、白人患者接受丁丙诺啡的比例分别为12.7%、18.7%、23.3%,接受纳洛酮的比例分别为14.4%、20.7%、22.9%,接受苯二氮䓬类的比例分别为23.4%、29.6%、37.1%。2016—2019年间OUD药物治疗获取的种族差异未见明显变化,且所有组别患者均有多次门诊就诊(黑人平均6.6次、西班牙裔6.7次、白人7.6次),提示差异在频繁医疗接触下仍持续存在。
要点
- 索引事件后180天内,黑人患者接受丁丙诺啡的比例为12.7%,西班牙裔为18.7%,白人为23.3%。
- 纳洛酮获取比例:黑人14.4%、西班牙裔20.7%、白人22.9%;苯二氮䓬类处方比例:黑人23.4%、西班牙裔29.6%、白人37.1%。
- 丁丙诺啡获取的种族差异未随时间改善:2016年黑人9.1% vs 白人21.6%,2019年黑人14.1% vs 白人25.5%。
- 所有组别在索引事件后180天内均有多次门诊就诊(黑人平均6.6次、西班牙裔6.7次、白人7.6次),差异在频繁医疗接触下仍持续。
- 研究对象为因残疾获得Medicare资格、发生OUD相关索引事件的黑人、西班牙裔和白人受益人。
适用人群与场景
- 2016—2019年Medicare按服务收费受益人40%随机样本中,因残疾获得Medicare资格、发生OUD相关索引事件的黑人、西班牙裔或白人患者。
- 索引事件包括:急诊或住院治疗的非致死性过量、注射用药相关感染住院、住院或寄宿康复或脱毒治疗。
研究设计与关键结果
- 研究类型:基于Medicare理赔数据的回顾性队列分析;样本:23,370名受益人的25,904次OUD相关索引事件,其中黑人3,937次(15.2%)、西班牙裔2,105次(8.1%)、白人19,862次(76.7%)。
- 索引事件后180天内丁丙诺啡获取率:黑人12.7%、西班牙裔18.7%、白人23.3%。
- 索引事件后180天内纳洛酮获取率:黑人14.4%、西班牙裔20.7%、白人22.9%。
- 索引事件后180天内苯二氮䓬类处方率:黑人23.4%、西班牙裔29.6%、白人37.1%。
- 丁丙诺啡获取的种族差异2016—2019年未见明显变化:2016年黑人9.1% vs 白人21.6%,2019年黑人14.1% vs 白人25.5%。
- 索引事件后180天内平均门诊就诊次数:黑人6.6次、西班牙裔6.7次、白人7.6次。
- 分析调整了受益人年龄、性别、索引事件类型、慢性共存疾病数量和居住州。
证据类型、等级与局限
- 证据类型:基于Medicare理赔数据的回顾性队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在因残疾参保且发生OUD相关索引事件的患者中,获取OUD治疗药物的种族和民族差异显著且未随时间改变。
- 作者认为,所有组别门诊就诊频率均高,表明差异在频繁医疗接触的情况下仍持续存在。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Since 2010, Black persons in the United States have had a greater increase in opioid overdose-related mortality than other groups, but national-level evidence characterizing racial and ethnic disparities in the use of medications for opioid use disorder (OUD) is limited.
METHODS: We used Medicare claims data from the 2016-2019 period for a random 40% sample of fee-for-service beneficiaries who were Black, Hispanic, or White; were eligible for Medicare owing to disability; and had an index event related to OUD (nonfatal overdose treated in an emergency department or inpatient setting, hospitalization with injection drug use-related infection, or inpatient or residential rehabilitation or detoxification care). We measured the receipt of medications to treat OUD (buprenorphine, naltrexone, and naloxone), the receipt of high-risk medications (opioid analgesics and benzodiazepines), and health care utilization, all in the 180 days after the index event. We estimated differences in outcomes according to race and ethnic group with adjustment for beneficiary age, sex, index event, count of chronic coexisting conditions, and state of residence.
RESULTS: We identified 25,904 OUD-related index events among 23,370 beneficiaries, with 3937 events (15.2%) occurring among Black patients, 2105 (8.1%) among Hispanic patients, and 19,862 (76.7%) among White patients. In the 180 days after the index event, patients received buprenorphine after 12.7% of events among Black patients, after 18.7% of those among Hispanic patients, and after 23.3% of those among White patients; patients received naloxone after 14.4%, 20.7%, and 22.9%, respectively; and patients received benzodiazepines after 23.4%, 29.6%, and 37.1%, respectively. Racial differences in the receipt of medications to treat OUD did not change appreciably from 2016 to 2019 (buprenorphine receipt: after 9.1% of index events among Black patients vs. 21.6% of those among White patients in 2016, and after 14.1% vs. 25.5% in 2019). In all study groups, patients had multiple ambulatory visits in the 180 days after the index event (mean number of visits, 6.6 after events among Black patients, 6.7 after events among Hispanic patients, and 7.6 after events among White patients).
CONCLUSIONS: Racial and ethnic differences in the receipt of medications to treat OUD after an index event related to this disorder among patients with disability were substantial and did not change over time. The high incidence of ambulatory visits in all groups showed that disparities persisted despite frequent health care contact. (Funded by the National Institute on Drug Abuse and the National Institute on Aging.).
参考来源
- Barnett ML, Meara E, Lewinson T, et al. Racial Inequality in Receipt of Medications for Opioid Use Disorder. N Engl J Med. 2023. PMID: 37163624. doi:10.1056/NEJMsa2212412
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。